Associated tags: Disorder, Obesity, Adenosine, Medication, Opioid use disorder, Pain, Gambling, Addiction, Drinking, Pharmaceutical industry, Patient, AUD
Locations: EUROPE, AUSTRIA, NEW YORK CITY, FAA, CHARLOTTESVILLE, VA, US, CLAIBORNE, AST, AUD, AE, UNITED STATES
Mr. Claiborne will be available for one-on-one and small group investor meetings during the conference.
Key Points:
- Mr. Claiborne will be available for one-on-one and small group investor meetings during the conference.
- To arrange a 1-on-1 please email [email protected], or contact your Roth sales team.
- For more information about the event or questions about registration, please contact your Roth representative.
Physician,
Prevalence,
Conference call,
Death,
Clinical trial,
Type,
United Kingdom,
Health,
Patient,
Hope,
Telephone,
Conference,
FDA,
EST,
AUD,
Observation,
Pharmaceutical industry,
Online shopping CHARLOTTESVILLE, Va., March 06, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on its regulatory strategy for AD04, the Company’s lead compound for the treatment of Alcohol Use Disorder (AUD).
Key Points:
- The Type C meeting is expected to provide Adial with confirmation of a clear clinical development plan.
- Adial is exploring partnerships with companies that have an established commercial presence and existing relationships with psychiatrists and addiction specialists.
- With an experienced partner, Adial believes it can rapidly penetrate the U.S. market given the expectation of AD04 being widely accessible, reasonably priced, and reimbursable.
- Furthermore, Adial is progressing discussions with five European country-level regulatory authorities: France, Sweden, Finland, the United Kingdom, and Germany.
The company will also present and discuss the findings from its subgroup analysis of ONWARD data.
Retrieved on:
Monday, February 27, 2023
Joseph Gunnar & Co., LLC acted as the sole placement agent for the offering.
Key Points:
- Joseph Gunnar & Co., LLC acted as the sole placement agent for the offering.
- The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No.
- The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the registration statement.
- A prospectus supplement relating to the shares of common stock was filed by Adial with the SEC on February 24, 2023.
Retrieved on:
Friday, February 24, 2023
Under the terms of the securities purchase agreement, Adial has agreed to sell 1,829,269 shares of common stock.
Key Points:
- Under the terms of the securities purchase agreement, Adial has agreed to sell 1,829,269 shares of common stock.
- Joseph Gunnar & Co., LLC is acting as the sole placement agent for the offering.
- The offering is expected to close on or about February 24, 2023, subject to the satisfaction of customary closing conditions.
- A prospectus supplement relating to the shares of common stock will be filed by Adial with the SEC.
Retrieved on:
Tuesday, February 21, 2023
CHARLOTTESVILLE, Va., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has secured meetings with regulatory authorities in the U.S. and Europe to discuss and develop plans for the clinical advancement of AD04 for alcohol use disorder toward potential approvals.
Key Points:
- In the United States, Adial has secured a Type C meeting with the Food and Drug Administration (FDA) in the second quarter of this year.
- This meeting will allow Adial and the FDA to discuss the clinical development program for AD04 in the U.S. and the most appropriate path toward possible approval.
- In Europe, Adial has meetings scheduled or planned with five national regulatory authorities in France, Sweden, Finland, the United Kingdom and Germany.
- Adial intends to seek from the agencies a clear understanding and direction toward the most expeditious path to approval.
Retrieved on:
Wednesday, February 1, 2023
Economics,
AUD,
Acquisition,
Sale,
Audit committee,
Burn,
Exercise,
Adenosine,
Pain,
Inflammation,
Pharmaceutical industry CHARLOTTESVILLE, Va., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate CEO, William Stilley, founder and former CEO of Adial.
Key Points:
- Under the terms of the agreement, Adenomed will have 120 days to exercise the option with the right to purchase two 30-day extensions.
- Upon exercise of the option Adial would receive $450,000, and then be reimbursed for any Purnovate expenditures incurred and paid after December 1, 2022.
- Through this transaction, Adenomed would assume all current Adial obligations related to Purnovate.
- If Adenomed exercises the option as expected, Adial would receive upfront non-dilutive funding and maintain meaningful downstream economics.
Retrieved on:
Monday, November 14, 2022
Sale,
Gambling,
Communication,
Marketing,
Mouse,
Alcoholism,
Fatty liver disease,
Opioid use disorder,
Infection,
Inflammatory Bowel Diseases,
Knowledge,
NASH,
Therapy,
Patient,
Weight loss,
Obesity,
Cancer,
Research,
Security (finance),
Nature,
General Services Administration,
Addiction,
Asthma,
Inflammation,
Administration,
Maintenance,
Pain,
Annual report,
Development,
Growth,
Diabetes,
Corporation,
Sucampo Pharmaceuticals,
AUD,
Adenosine,
Drinking,
Research and development,
Pharmaceutical industry,
Mallinckrodt,
Indivior CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2022.
Key Points:
- CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2022.
- Overall, we have made significant strides during the third quarter and look forward to providing further updates as developments unfold.
- Cary Claiborne was promoted to President and Chief Executive Officer of Adial from his previous role as Chief Operating Officer.
- Mr. Claiborne was appointed Chief Operating Officer of Adial in December 2021 after previously being named to the Board of Directors.
Retrieved on:
Thursday, October 22, 2020
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.
Key Points:
- InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- View original content to download multimedia: http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-a...
